Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer

49Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.

Cite

CITATION STYLE

APA

Piqué, L., Martinez de Paz, A., Piñeyro, D., Martínez-Cardús, A., Castro de Moura, M., Llinàs-Arias, P., … Esteller, M. (2019). Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. Oncogene, 38(45), 7106–7112. https://doi.org/10.1038/s41388-019-0936-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free